Show simple item record

dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorSsenyonga, Ronald
dc.contributor.authorLamorde, Mohammed
dc.contributor.authorBlessborn, Daniel
dc.contributor.authorTarning, Joel
dc.date.accessioned2022-01-12T12:43:36Z
dc.date.available2022-01-12T12:43:36Z
dc.date.issued2019
dc.identifier.citationByakika-Kibwika, P., Ssenyonga, R., Lamorde, M., Blessborn, D., & Tarning, J. (2019). Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine. BMC infectious diseases, 19(1), 1-7. https://doi.org/10.1186/s12879-019-4647-2en_US
dc.identifier.urihttps://doi.org/10.1186/s12879-019-4647-2
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1232
dc.description.abstractTreatment for severe malaria must be prompt with effective parenteral antimalarial drugs for at least 24 h to achieve fast parasite clearance, and when the patient can tolerate oral therapy, treatment should be completed with effective artemisinin based combination therapy (ACT) for complete parasite clearance and to prevent recrudescence. We evaluated piperaquine concentration and malaria treatment outcomes among Ugandan children treated for severe malaria with intravenous artesunate (AS) or quinine (QN) plus dihydroartemisininpiperaquine (DP), in Tororo District Hospital in Eastern Uganda.en_US
dc.language.isoenen_US
dc.publisherBMC infectious diseasesen_US
dc.subjectPiperaquineen_US
dc.subjectPharmacokineticsen_US
dc.subjectMalariaen_US
dc.subjectChildrenen_US
dc.titlePiperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquineen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record